Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Activated T cells (Primary) ; Alemtuzumab; Fludarabine; Melphalan; Rimiducid; Tacrolimus
  • Indications Hodgkin's disease; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 16 Jul 2019 Biomarkers information updated
    • 03 Jun 2014 New source identified and integrated (M.D. Anderson Cancer Centre: 2012-0501)
    • 02 Jan 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record..

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top